✦ LIBER ✦

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

✍ Scribed by B. Ahrén; A. Schweizer; S. Dejager; E. B. Villhauer; B. E. Dunning; J. E. Foley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The influence of hepatic impairment on t

✍ Y.-L. He; R. Sabo; J. Campestrini; Y. Wang; M. Ligueros-Saylan; K. C. Lasseter; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 240 KB

Absolute bioavailability of sitagliptin,

✍ Arthur Bergman; David Ebel; Fang Liu; Julie Stone; Amy Wang; Wei Zeng; Li Chen; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

Effect of renal impairment on the pharma

✍ U. Graefe-Mody; C. Friedrich; A. Port; A. Ring; S. Retlich; T. Heise; A. Halabi; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 646 KB

Hormonal and metabolic effects of mornin

✍ Yan-Ling He; Jessica Valencia; Yiming Zhang; Sherwyn L. Schwartz; Monica Liguero 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 974 KB

Dipeptidyl peptidase-4 inhibitors in the

✍ C. F. Deacon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 711 KB

Saxagliptin: a new dipeptidyl peptidase-

✍ Carolyn F. Deacon; Jens J. Holst 📂 Article 📅 2009 🏛 Springer Healthcare Communications 🌐 English ⚖ 223 KB